Anticoagulants Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Anticoagulants Market size accounted for more than USD 39.2 billion in 2022 and is estimated to grow at a CAGR of over 9.5% from 2023 to 2032. Driven by the surging occurrence of chronic disorders worldwide.
Rising prevalence of chronic disorders such as deep vein thrombosis, and cardiovascular diseases which lead to blood clot formation has increased the need for anticoagulants. As per CDC, although the precise number of people diagnosed with deep vein thrombosis remains obscure, the condition can affect around 900,000 people every year in the U.S. alone. Moreover, the rising adoption of novel oral anticoagulants (NOACs) will further create a plethora of opportunities for market expansion. Benefits such as the rapid onset action, shorter half-life, and predictable pharmacokinetic action, have bolstered the adoption of NOACs.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Anticoagulants Market size in 2022: | USD 39.2 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 - 2032 CAGR: | 9.8 |
| 2023 Value Projection: | USD 95.2 Billion |
| Historical Data for: | 2018 to 2022 |
| No of Pages: | 181 |
| Tables, Charts & Figures: | 276 |
| Segments Covered: | Drug Category, Route of Administration, Application, Distribution Channel and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The COVID-19 pandemic had a moderate impact on the anticoagulants market owing to supply chain disruptions caused by prolonged lockdowns. However, the surging prevalence of venous thromboembolism that led to blood clots in the veins of COVID-19 patients increased product uptake. For instance, in January 2021, WHO rolled-out a recommendation stating patients diagnosed with COVID-19, including confirmed and suspected cases, should have access to follow-up care with low-dose anticoagulants.
Recent breakthroughs in genetic testing and pharmacogenomics will positively impact the industry landscape through 2032. These advancements have paved the way for personalized medicine approaches in anticoagulation therapy. Genetic variations can influence an individual's response to anticoagulant medications, including the risk of bleeding or thrombotic events. Tailoring the choice and dosing of anticoagulants based on a patient's genetic profile can significantly improve treatment outcomes and reduce adverse events.
Based on the drug category, the anticoagulants market revenue from the Factor Xa inhibitor segment will reach USD 58.4 billion by 2032. High availability of Factor Xa inhibitors globally is contributing to segment growth. These drugs can lower the risk of stroke and venous thrombosis. Additionally, people taking them do not require frequent blood tests.
With respect to application, the anticoagulants market from coronary heart disease segment was worth over USD 21.8 billion in 2022. Growing prevalence of coronary heart disease attributed to the surging adoption of a sedentary lifestyle has increased the need for anticoagulants. As per the National Institutes of Health, coronary artery disease affects around 18.2 million American adults, making it the most common heart disease in the U.S. In addition, surging elderly population that is highly susceptible to this disorder will further increase product uptake.
North America held approximately 60.5% of the anticoagulants market share in 2022. Growing healthcare spending in the region is positively impacting industry landscape. Moreover, the rising burden of cardiovascular disorders has further increased the need for anticoagulants in the region. North America is also home to major industry players such as Johnson and Johnson, Pfizer, and others focusing on product innovations to extend their footprint.
By Drug Category
By Route of Administration
By Application
By Distribution Channel
The above information is provided for the following regions and countries:
The market size of anticoagulants was valued at around USD 39.2 billion In 2022 and will grow at over 9.5% CAGR from 2023 to 2032, attributed to the rising occurrence of chronic disorders globally.
Major anticoagulants industry players include Johnson and Johnson, Boehringer Ingelheim, Daiichi Sankyo Company, Sanofi, Shenzhen Hepalink, Amphastar Pharmaceuticals, Inc., and Pfizer, among others.
Based on the drug category, industry size from the Factor Xa inhibitor segment will be worth about USD 58.4 billion by 2032, owing to its high availability.
North America market anticoagulants accounted for over 60.5% of the industry share in 2022, on account of rising healthcare spending in the region.